Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7572834 | TEVA | Rasagiline formulations and processes for their preparation |
Dec, 2026
(2 years from now) |
Market Authorisation Date: 16 May, 2006
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL